To determine the dose and treatment duration of ABN401 that was required to inhibit c-MET phosphorylation in preclinical models, ABN401 was administered at doses of 10 and 30 mg/kg, and tumor samples were collected at nine time-points, as shown in Table S3. This evidence concerns the gene MET and neoplasm.